The giant French drugmaker Sanofi (NASDAQ: SNY) isn't exactly an obvious candidate for a stock that's likely to beat the market, but its total return of around 8.5% this year is undoubtedly superior to the market's losses of more than 15.4%. Let's take a peek at Sanofi to appreciate why it could be a great pick for the more conservative portion of your holdings. Sanofi sells Dupixent, which treats atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.